PainChek has productive final FDA De Novo clearance meeting
Filed with ASX · · 3 pages · English
Summary by 6ix AI
PainChek Ltd has announced a productive meeting with the FDA regarding its De Novo regulatory clearance process for its pain assessment application. The meeting addressed final questions related to recent clinical trial results and established a revised timeline for submission and decision. PainChek is compiling additional information to align with FDA feedback, aiming for submission by the end of June. The FDA has committed to a decision within a specified timeframe after receiving the final submission, potentially allowing for market entry later this year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from PainChek
- PainChek partners with Eldermark to expand US market reach
- R&D Tax Refund, FDA Review of Adult App & Infant App Launch
- PainChek completes Entitlement Offer raising AUD $5.1 m
- PainChek Implementations, Market and International Expansion
- Prospectus
Later from PainChek
- PainChek Reports Strong Quarterly Sales Growth
- Final US FDA De Novo Clearance Submission Completed
- Strongly Supported A$7.5m Placement to Drive Int. Growth
- Preliminary Final Report
- Compelling Clinical and Economic Results in Scottish Pilot
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek